7 August 2018Americas

LSIPR 50 2018: Richard Gonzalez

Name: Richard Gonzalez

Organisation: AbbVie

Position: CEO and Chairman

As CEO and chairman of the board at AbbVie, Richard Gonzalez has overseen a biopharmaceutical company that employs nearly 30,000 people and markets medicines in more than 175 countries since 2012.

Before AbbVie’s separation from Abbott, Gonzalez served as executive vice president of Abbott’s pharmaceutical products group, where he led the global pharmaceutical business, including commercial operations, research and development and manufacturing.

For 2018, AbbVie said it would take one single digit price increase and would continue to act responsibly with respect to drug pricing.

At the beginning of the year, AbbVie increased the price of Humira (adalimumab), the blockbuster rheumatoid arthritis/inflammatory disease treatment, by 9.7%.

Wells Fargo analyst David Maris reportedly said that this single price increase could add $1.2 billion to the US healthcare system’s drug costs this year.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk